Investing.com - Oramed reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Oramed announced earnings per share of $-0.21 on revenue of $674.0K. Analysts polled by Investing.com anticipated EPS of $-0.18 on revenue of $800K.
Oramed shares are down 15.41% from the beginning of the year, still down 61.70% from its 52 week high of $31.54 set on November 3, 2021. They are under-performing the Nasdaq which is down 2.92% from the start of the year.
Oramed follows other major Healthcare sector earnings this month
Oramed's report follows an earnings missed by Neogen on December 21, 2021, who reported EPS of $0.1 on revenue of $130.52M, compared to forecasts EPS of $0.17 on revenue of $129.06M.
Tilray had beat expectations on Monday with second quarter EPS of $0.0126 on revenue of $155.15M, compared to forecast for EPS of $-0.0833 on revenue of $171.79M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar